Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 10/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KHK | P50053 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5376704 | 0.86 | METAP2 (0.47) | METAP2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5376455 | 0.85 | METAP2 (0.46) | METAP2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5385028 | 0.85 | METAP2 (0.67) | METAP2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5382956 | 0.84 | METAP2 (0.47) | METAP2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5384607 | 0.84 | METAP2 (0.41) | METAP2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5381901 | 0.84 | METAP2 (0.42) | METAP2NPSR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5381220 | 0.84 | METAP2 (0.43) | METAP2NPSR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5373504 | 0.83 | METAP2 (0.62) | METAP2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5377242 | 0.82 | METAP2 (0.65) | METAP2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5372169 | 0.82 | METAP2 (0.41) | METAP2NPSR1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050222212-A1 | Non-peptide, reversible inhibitors of bacterial methionine aminopeptidases, e.g., 3-anilino-5-(thiophen-2-ylmethylthio)-1,2,4-triazole | MARINO JOSEPH P | 2005-10-06 | — | — | US | claimed |
| EP-1576092-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2003083068-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | claimed |
| US-7304082-B2 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION | 2005-12-01 | — | — | US | disclosed |
| US-20050222212-A1 | Non-peptide, reversible inhibitors of bacterial methionine aminopeptidases, e.g., 3-anilino-5-(thiophen-2-ylmethylthio)-1,2,4-triazole | MARINO JOSEPH P | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | METAP2, METAP1, DNPEP | METAP2 1/4885NPSR1 2820/4885ALDH1A1 1754/4885 |
| US-20050222212-A1 | Non-peptide, reversible inhibitors of bacterial methionine aminopeptidases, e.g., 3-anilino-5-(thiophen-2-ylmethylthio)-1,2,4-triazole | METAP1, ANPEP, METAP2 | METAP2 3/4885NPSR1 1497/4885ALDH1A1 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.